OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial Apr 12, 2019
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer Feb 1, 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator Jan 31, 2019
